Literature DB >> 34979558

Intestinal Persistence of Colonizing Escherichia coli Strains, Especially ST131-H30, in Relation to Bacterial and Host Factors.

James R Johnson1,2, Connie Clabots1, Stephen B Porter1, Tricia Bender1, Brian D Johnston1,2, Paul Thuras1,2.   

Abstract

BACKGROUND: Superior gut colonization may underlie the pandemic emergence of the resistance-associated H30 subclone of Escherichia coli sequence type 131 (ST131-H30). Little is known about the associated host and bacterial characteristics, or the comparative persistence of non-ST131 intestinal E. coli.
METHODS: Generic and fluoroquinolone-resistant E. coli isolates from volunteers' serial fecal samples underwent clonal analysis and extensive polymerase chain reaction (PCR)-based characterization (phylogroup, selected sequence types, virulence genes). Kaplan-Meier survival analysis and Cox proportional hazards survival analysis using penalized regression (a machine-learning method) were used to identify correlates of strain persistence.
RESULTS: Screening of 2005 subjects at the Minneapolis VA Medical Center identified 222 subjects (117 veterans, 105 human and animal household members) for longitudinal fecal surveillance. Analysis of their 585 unique-by-subject fecal E. coli strains identified multiple epidemiological, ecological, and bacterial correlates of strain persistence. ST131-H30, a strong univariable correlate of persistence, was superseded in multivariable analysis by outpatient status, fluoroquinolone resistance, and diverse (predominantly iron uptake-related) virulence genes.
CONCLUSIONS: ST131-H30 exhibits exceptional intestinal persistence, possibly due to a combination of fluoroquinolone resistance and virulence factors, which may be primarily colonization factors. This identifies both likely contributors to the ST131-H30 pandemic and potential targets for interventions against it. Published by Oxford University Press for the Infectious Diseases Society of America 2022.

Entities:  

Keywords:  zzm321990 Escherichia colizzm321990 ; ST131; ecology; fluoroquinolone resistance; intestinal colonization; machine learning; molecular epidemiology; multivariable modeling; surveillance; virulence factors

Mesh:

Substances:

Year:  2022        PMID: 34979558      PMCID: PMC9200155          DOI: 10.1093/infdis/jiab638

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  36 in total

1.  Virulence factors predict Escherichia coli colonization patterns among human and animal household members.

Authors:  Andrew C Murray; Michael A Kuskowski; James R Johnson
Journal:  Ann Intern Med       Date:  2004-05-18       Impact factor: 25.391

2.  Development of an allele-specific PCR for Escherichia coli B2 sub-typing, a rapid and easy to perform substitute of multilocus sequence typing.

Authors:  Olivier Clermont; Julia K Christenson; Anne-Sophie Daubié; David M Gordon; Erick Denamur
Journal:  J Microbiol Methods       Date:  2014-03-28       Impact factor: 2.363

Review 3.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

4.  Long-Term Carriage of Ciprofloxacin-Resistant Escherichia coli Isolates in High-Risk Nursing Home Residents.

Authors:  Miriam D Ismail; Ting Luo; Sara McNamara; Bonnie Lansing; Evonne Koo; Lona Mody; Betsy Foxman
Journal:  Infect Control Hosp Epidemiol       Date:  2016-01-19       Impact factor: 3.254

Review 5.  Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem.

Authors:  Thomas A Russo; James R Johnson
Journal:  Microbes Infect       Date:  2003-04       Impact factor: 2.700

6.  Extraintestinal virulence is a coincidental by-product of commensalism in B2 phylogenetic group Escherichia coli strains.

Authors:  Tony Le Gall; Olivier Clermont; Stéphanie Gouriou; Bertrand Picard; Xavier Nassif; Erick Denamur; Olivier Tenaillon
Journal:  Mol Biol Evol       Date:  2007-08-19       Impact factor: 16.240

7.  Clinical and molecular epidemiology of Escherichia coli sequence type 131 among hospitalized patients colonized intestinally with fluoroquinolone-resistant E. coli.

Authors:  Jennifer H Han; Brian Johnston; Irving Nachamkin; Pam Tolomeo; Warren B Bilker; Xiangqun Mao; Connie Clabots; Ebbing Lautenbach; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

8.  Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009.

Authors:  James R Johnson; Marie-Hélène Nicolas-Chanoine; Chitrita DebRoy; Mariana Castanheira; Ari Robicsek; Glen Hansen; Scott Weissman; Carl Urban; Joanne Platell; Darren Trott; George Zhanel; Connie Clabots; Brian D Johnston; Michael A Kuskowski
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 6.883

9.  Colonisation with ESBL-producing and carbapenemase-producing Enterobacteriaceae, vancomycin-resistant enterococci, and meticillin-resistant Staphylococcus aureus in a long-term care facility over one year.

Authors:  Catherine Ludden; Martin Cormican; Akke Vellinga; James R Johnson; Bernie Austin; Dearbháile Morris
Journal:  BMC Infect Dis       Date:  2015-04-01       Impact factor: 3.090

10.  Global dissemination of a multidrug resistant Escherichia coli clone.

Authors:  Nicola K Petty; Nouri L Ben Zakour; Mitchell Stanton-Cook; Elizabeth Skippington; Makrina Totsika; Brian M Forde; Minh-Duy Phan; Danilo Gomes Moriel; Kate M Peters; Mark Davies; Benjamin A Rogers; Gordon Dougan; Jesús Rodriguez-Baño; Alvaro Pascual; Johann D D Pitout; Mathew Upton; David L Paterson; Timothy R Walsh; Mark A Schembri; Scott A Beatson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-31       Impact factor: 11.205

View more
  1 in total

1.  Bacteriophage Cocktail and Microcin-Producing Probiotic Escherichia coli Protect Mice Against Gut Colonization With Multidrug-Resistant Escherichia coli Sequence Type 131.

Authors:  Stephen B Porter; Brian D Johnston; Dagmara Kisiela; Connie Clabots; Evgeni V Sokurenko; James R Johnson
Journal:  Front Microbiol       Date:  2022-04-25       Impact factor: 6.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.